Pro-Dex, Inc.
NASDAQ:PDEXMedical - Instruments & Supplies
+$3.54 today
- Market cap
- $204.61M
- Beta
- -0.00
- P/E (TTM)
- 17.1
- EPS (TTM)
- $3.75
Volume 0.04M
Average 0.04M
PDEX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Pro-Dex, Inc.NASDAQ: PDEX
Stock-Based Compensation · Q3 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q3 FY2026 stock-based compensation of $186K rose 17.7% year over year, behind the +59.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 13.4% from the prior quarter. Over 3 fiscal years it compounded at -24.2% a year.
Context
- Stock-based compensation amounted to 0.8% of revenue in FY2025, down 0.3 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +17.7% toward the trailing-twelve-month pace of +59.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 555K USD
- Year-over-year change
- -8.3%
- 4-year CAGR
- -18.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 555K | -8.3% |
| FY2024 | 2024-06-30 | 605K | -21.0% |
| FY2023 | 2023-06-30 | 766K | -39.9% |
| FY2022 | 2022-06-30 | 1.28M | +0.0% |
| FY2021 | 2021-06-30 | 1.28M | — |
Stock-Based Compensation vs competitors
How PDEX compares with its peers on the latest reported figures
- PDEX's LTM Mar 2026 stock-based compensation of $665K is the smallest of the 9 companies compared; the peer median is $4.33M.
- Its year-over-year change of +59.1% is the 3rd highest of 9, against a peer median of -22.9%.
- Stock-based compensation amounts to 0.9% of revenue for PDEX, versus a peer median of 4392.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $2.3B | +49501.8% | -33.1% | 44751.8% | |
| LTM Mar 2026 | $109.65M | +24888.0% | +373.5% | 27627.6% | |
| LTM Mar 2026 | $4.63M | -43.5% | +57.4% | — | |
| LTM Mar 2026 | $4.45M | -34.7% | +0.4% | 7810.5% | |
| LTM Mar 2026 | $4.21M | +10.0% | +0.1% | 12.3% | |
| LTM Mar 2026 | $1.83M | -42.1% | -16.4% | — | |
| LTM Mar 2026 | $1.02M | -11.2% | -15.5% | 974.3% | |
| LTM Mar 2026 | $1.02M | -69.4% | -33.1% | 1.8% | |
| LTM Mar 2026 | $665K | +59.1% | -24.2% | 0.9% | |
| Peer median (excluding PDEX) | $4.33M | -22.9% | -7.7% | 4392.4% | |
Competitors are the stored peer set for PDEX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Net Income | 4.57M | 4.57M | 7.07M | 2.13M | 8.98M |
| Depreciation & Amortization | 726K | 726K | 857K | 1.16M | 1.24M |
| Deferred Income Tax | (63K) | (63K) | 264K | (1.56M) | 140K |
| Stock-Based Compensation | 1.28M | 1.28M | 766K | 605K | 555K |
| Change in Working Capital | (6.54M) | (6.54M) | 396K | (225K) | (10.45M) |
| Accounts Receivables | (4.45M) | (4.45M) | 5.43M | (3.94M) | (2.55M) |
| Inventory | (4.24M) | (4.24M) | (3.49M) | 898K | (6.94M) |
| Accounts Payables | 1.99M | 1.99M | (1.15M) | 2.44M | 179K |
| Other Working Capital | 162K | 162K | (394K) | 376K | (1.14M) |
| Other Non-Cash Items | (820K) | (820K) | (3.9M) | 4.1M | (2.14M) |
| Operating Cash Flow | (847K) | (847K) | 5.46M | 6.2M | (1.68M) |
| Capital Expenditures | (1.67M) | (1.67M) | (974K) | (983K) | (1.25M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (334K) | (334K) | 0 | (1.25M) | 0 |
| Sales of Investments | 770K | 770K | 89K | 0 | 1.31M |
| Other Investing Activities | (33K) | (33K) | 0 | 0 | (304K) |
| Investing Cash Flow | (1.24M) | (1.24M) | (885K) | (2.23M) | (238K) |
| Debt Repayment | 8.79M | 756K | (809K) | (816K) | 3.48M |
| Common Stock Issued | 96K | 0 | 0 | 0 | 42K |
| Common Stock Repurchased | (5.54M) | (1.61M) | (1.55M) | (3.51M) | (3.5M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (4.14M) | 60K | (134K) | 50K | (305K) |
| Financing Cash Flow | (790K) | (790K) | (2.49M) | (4.27M) | (292K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (2.87M) | (2.87M) | 2.09M | (305K) | (2.21M) |
| Free Cash Flow | (2.52M) | (2.52M) | 4.49M | 5.22M | (2.93M) |
Pro-Dex, Inc.
NASDAQ:PDEX
Intrinsic Alpha fair value
Locked
Current Price
$63.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.